SOLE DECLARATION FOR PATENT APPLICATION

As the below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

	LLS AND MONOC	CLONAL ANTI	BODIES	the specification of whi
was filed on February				as Applicati
Serial Numberamended on				and w
amended on		(if applicable)		
I hereby state that I have reviewed an amended by any amendment referred to	id understand the conten	ts of the above ider	ntified specification	n, including the claims,
I acknowledge the duty to disclose info 37, Code of Federal Regulations, §1.56(a	ormation which is materia	al to the examination	n of this applicatio	n in accordance with Tit
	Prior Foreign A	opplication(s)		
I hereby claim foreign priority benefits or's certificate listed below and have also ng date before that of the application or	under Title 35, United Sta	ate Code, §119 of a	ny foreign applica or patent or invento	tion(s) for patent or inve or's certificate having a f
Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed Under 35 U.S.C. 119
				Yes No
· .				Yes No C
				Yes No 🗆
		<u> </u>		Yes 🗌 No 🗌
I hereby claim the benefit under Title 35 s the subject matter of each of the claim: rovided by the first paragraph of Title 35, efined in Title 37, Code of Federal Regul, ational or PCT international filing date of	s of this application is not , United States Code, §11 ations, §1,56(a) which oc	20 of any United States	or United States a	pplication in the manner
Application Serial Number	Date of Filing		Status — Patented,	
Number	(day, month, year)		Pending	, Abandoned
				
		j		

2100-2-1 Rev. 11/83

All correspondence and telephone communications should be addressed to Banner, Birch, McKie and Beckett, One Thomas Circle, N.W., Washington, D.C. 20005, telephone number (202) 296-5500, which is also the address and telephone number of each of the above listed attorneys.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature	Churt of	Date Feb. 16, 178	
Full Name of Sole Inventor		Curt	I.
Residence _	Family Name Baltimore, Maryland	First Given Name	Second Given Name
Citizenship _	United States		
Post Office Address	2217 South Road, Baltime	ore, Maryland 21209	

LAW OFFICES
BANNER, BIRCH, MCKIE & BECKETT
ONE THOMAS CIRCLE, N.W.
WASHINGTON, D.C. 20005
(202) 296-5500

2100-2-2 Rev. 11/83

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	?
CURT I. CIVIN	{
Serial No.: 670,740	Group Art Unit 127
Filed: February 6, 1984	Examiner: E. C. Weimar
For: HUMAN STEM CELLS AND MONOCLONAL ANTIBODIE	· · · · · · · · · · · · · · · · · · ·

DECLARATION

Honorable Commissioner of Patents & Trademarks
Washington, D. C. 20231

Sir:

- I, Curt I. Civin (referred to herein as the inventor), do hereby declare:
- 1. THAT, I am the sole inventor of the subject application;
- 2. THAT, any subject matter claimed in the present application that is common to the subject matter disclosed in Strauss et al, "MY-10, A Human Hematopoietic Progenitor Cell Surface Antigen Identified by a Monoclonal Antibody", Experimental Hematology, (Lawrence), 11 (Suppl. 14), p. 205, 1983, is derived from the work of the inventor, is not the original contribution of the co-author who is not a co-inventor, and is a publication of the inventor's presently claimed invention;
- 3. THAT, the non-inventor, co-author of the article referred to in paragraph 2, Dr. Strauss, did not contribute in an inventive capacity to the subject matter claimed in the subject application; and
- 4. THAT, in the aforesaid article, Dr. Strauss contributed by performing experiments under my supervision.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

4/15/86 (Date)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

CURT I. CIVIN

Serial No. 670,740

Filed: February 6, 1984

For: HUMAN STEM CELLS AND MONOCLONAL ANTIBODIES

Open Art Unit: 127

Examiner: E. C. Weimar

Memory 1984

RULE 132 DECLARATION

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

- I, CURT I. CIVIN, do declare:
- 1. THAT, I am the inventor of the subject application, Serial No. 670,740.
- 2. THAT, I am Director of Pediatric Oncology at the Oncology Center of Johns Hopkins University, Baltimore, Maryland.
- 3. THAT, at my direction and under my supervision a series of experiments were performed to determine the reactivity of the RFB-1 antibody of Bodger to various peripheral blood cell types. The antibody was obtained from Dr. Bodger. The results of those experiments are shown in attached Exhibit 1.
- 4. THAT, the experiments were performed by use of known antibodies such as leu M3, leu 15, leu 14, leu 11, leu 5, leu 1, which type for specific blood cell types, and by use of the fluorescence activated cell sorter. The methodology used is specifically described in Experimental Hematology, Vol. 15, pp. 10-17 (1987) in the Materials & Methods section.
 - 5. THAT, my own blood was used as a source of peripheral blood.
- 6. THAT, RFB-1 labels lymphocytes in the blood, as demonstrated on page 5 of the attached data sheets.
- 7. THAT, RFB-1 labels monocytes in the blood, as demonstrated on page 6, 16 and 18 of the attached data sheets.
- 8. THAT, RFB-1 labels blood T cells which are leu 1⁺ and leu 5⁺, as demonstrated on pages 7 and 9 of the attached data sheets.
- 9. THAT, RFB-1 labels blood NK cells, as demonstrated at pages 11 and 15 of the attached data sheets.

- 10. THAT, RFB-1 labels blood B cells, as demonstrated at page 13 of the attached data sheets.
 - 11. THAT, these results were confirmed in multiple other experiments.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application of any patent issued thereon.

Dated: May 28, 1987

Curt I. Civin

Double LAbel Experiment on Peripheral Blood Lymphis, Graigs, is manos. boner: curt Cirin # of cells / tasty=11 x 106 ... + NOPC ... P.B. L, GM + In GI-PE + RFB-1+ F Leu 5 - PE INKU(9) + #RF B. 1 + Leu Me-PE tbcell 10 + - RFB - 1 +leu: 14 - PE +=RFB-1+ lau 15-PE + - RFB-1+ TFR-PE + : RFB-1+ Leu M3 -(KA 12-8) PB L.G.M + Boenstein + I96, -PE + Brenstein + + Leu (- PE Brenstein -+ Leu 5-PE + Brenstein + + Leu 16-PE Beenstein + Leu 14-PE Beenstein + + Leu 15-PE Brenotein + TFR-PE Baenstain -Leu M3-P

cont. Lille or Staining